Skip to main content

Table 1 Demographic, clinical and pathological features of patients with IgA nephropathy

From: Serum levels of tumor necrosis factor alpha in patients with IgA nephropathy are closely associated with disease severity

Characteristics Values
Patients numbers 147
Cytokines–biopsy time intervala (months) 27.93 (6.17–63.37)
Mean age (yr) 35 (29–45)
Male, n (%) 71 (48.3)
Systolic BP (mmHg) 120 (110–130)
Diastolic BP (mmHg) 75 (70–80)
Mean arterial pressure (mmHg) 90 (83–97)
Urinary red blood cell (/μL) 29 (7–79)
Urinary protein to serum creatinine ratio (mg/g Cr) 595 (244–1305)
24-h urine protein excretion (g/24 h) 0.82 (0.38–1.55)
  < 0.3 27 (18.4%)
 0.3–0.99 59 (40.1%)
 1.0–2.99 46 (31.3%)
  ≥ 3 15 (10.2%)
Serum creatinine (mg/dL) 1.07 (0.84–1.39)
Serum IgA (g/L) 2.22 (1.82–3.22)
Cystatin C (mg/dL) 1.06 (0.93–1.57)
eGFR (mL/min•1.73m2)b 79.29 (60.00–104.29)
CKD Stagesc, n (%)
 1 57 (38.8)
 2 49 (33.3)
 3a 22 (15.0)
 3b 8 (5.4)
 4 5 (3.4)
 5 6 (4.1)
Oxford classificationd, n (%)
 M0/ M1 16(10.9), 131(89.1)
 E0/E1 113(76.9), 34(23.1)
 S0/S1 24(16.3), 123(83.7)
 T0/T1/T2 45(30.6), 65(44.2), 37(44.2)
 C0/C1/C2 66(44.9), 66(44.9), 15(10.2)
Medical treatments, n (%)
 Untreated 35 (23.8)
 Corticosteroids 71 (48.3)
 Immunosuppressants 76 (51.7)
 ACE-Is/ARBs 99 (67.3)
  1. Data are presented as median (interquartile range) or frequency in percent
  2. BP: blood pressure; 1 mmHg = 0.133Kpa; eGFR: estimated glomerular filtration rate; ACE-Is: angiotensin converting
  3. enzyme inhibitors; ARBs: angiotensin II receptor blockers. M: mesangial hypercellularity score < 0.5 (M0) or > 0.5 (M1);
  4. E: endocapillary hypercellularity absent (E0) or present (E1); S: segmental glomerulosclerosis absent (S0) or present (S1),
  5. presence or absence of podocyte hypertrophy/tip lesions in biopsy specimens with S1; T: tubular atrophy/interstitial
  6. fibrosis < 25% (T0), 26–50% (T1), or > 50% (T2); C: cellular/fibrocellular crescents absent (C0), present in at least 1
  7. glomerulus (C1), in > 25% of glomeruli (C2)
  8. aTime interval between renal biopsy of patients with IgA nephropathy and sample collection
  9. beGFR was calculated according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [19]
  10. cCKD stages 1–5 were divided by eGFR≥90 (G1), 60–89 (G2), 45–59 (G3a), 30–44 (G3b), 15–29 (G4), and < 15 (G5) mL/min/1.73 m2, respectively, according to the new KDIGO (Kidney Disease: Improving Global Outcomes) classification [20]
  11. dDetermined in accordance with the Oxford classification [5]